New Study: OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018

From: Fast Market Research, Inc.
Published: Sun May 03 2015


GlobalData estimates that the 2013 sales for the Cushing's syndrome (CS) therapeutic market was approximately $179m across the 6MM covered in this report. Pharmaceutical and biotechnology companies that are investing their attention, time, and financial resources in the CS field, have adopted a myriad of research and development (R&D) strategies. One notable example is the fact that drug developers are focused on developing superior, next-generation inhibitors of cortisol synthesis in the adrenal glands. Steroidogenesis inhibitors were responsible for approximately 28% of total drug sales in the 6MM in 2013, equating to around $50m. As a consequence of this trend, GlobalData expects overall revenues generated by this drug class to increase by approximately 390% to reach around $247m, encompassing 49% of total drug sales in the 6MM in 2018. The expansion in this segment of the CS market is fuelled by the introduction of premium-priced pharmacological agents such as Novartis' LCI699 and Cortendo AB's NormoCort (COR-003) in the US, as well as the arrival of HRA Pharma's Ketoconazole HRA (ketoconazole) to the European CS stage. One of the greatest unmet needs in this indication is a lack of effective drugs directed against the underlying cause of Cushing's disease (the pituitary tumor). Despite this demand, pharmaceutical companies are continuing to adopt a strategy that simply targets the adrenal glands. As a result, there is a vast amount of room for new or existing players to penetrate the market and capture considerable patient share.

Full Report Details at
- http://www.fastmr.com/prod/990770_opportunityanalyzer_cushings.aspx?afid=301

Highlights

Key Questions Answered

* Although the current standard of care (ketoconazole) is cheap and reasonably effective in most CS patients, it possesses worrying safety profiles, inconvenient dosing schedules, is difficult to obtain and can display waning efficacy over time. Newer medical treatments, for example, Novartis' Signifor (pasireotide) and Corcept Therapeutics' Korlym (mifepristone) address only some of these issues; yet, present their own limitations. The CS market is still marked by the existence of a multitude of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the CS market?
* The late-stage CS pipeline is sparsely populated; however, those drugs in development will be a strong driver of CS market growth. Which of these drugs will attain high sales revenues during 2013-2018? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Key Findings

* One of the main drivers influencing growth in the Cushing's syndrome market will be the introduction of second-generation steroidogenesis inhibitors, LCI699 and NormoCort (COR-003), in the US, which will rival existing standard of care medical treatments.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Allergic Conjunctivitis - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018
- OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »